Please login to the form below

Not currently logged in
Email:
Password:

bribery

This page shows the latest bribery news and features for those working in and with pharma, biotech and healthcare.

Novartis bribery probe in Greece ‘could affect general election’

Novartis bribery probe in Greece ‘could affect general election’

In March, Novartis executives promised its investors it would take fast and decisive action if the ongoing probe reveals any wrongdoing and had strengthened its internal processes to prevent bribery and

Latest news

More from news
Approximately 15 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    One of the most serious concerns is bribery, corruption and fraud, well-known problems in the country in recent times. ... So how does AZ ensure it doesn’t get entangled in bribery or corruption in China?

  • Risky business for pharma Risky business for pharma

    to consider, including but not limited to bribery and corruption, money laundering, competition and antitrust, cybersecurity, data privacy and regulation and compliance. ... posing the most significant risks overall”, perhaps due to continued

  • Stress testing for the perfect compliance storm Stress testing for the perfect compliance storm

    Yet the industry often hits the headlines for all the wrong reasons, with regulators imposing multibillion dollar settlements for compliance failings including corruption and bribery. ... However, EY’s Global Fraud Survey 2016 shows 11% of company

  • Harnessing commercial innovation Harnessing commercial innovation

    However, the situation in China was about to change significantly. Christian took up his China Region post in August 2013, when the full ramifications of the bribery scandal at GlaxoSmithKline had

  • The Heart of the Matter 5 - the only way is ethics The Heart of the Matter 5 - the only way is ethics

    The strengthening of international regulations around anti-bribery – and renewed vigour in their enforcement – has placed pharmaceutical companies under unparalleled scrutiny.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics